<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485808</url>
  </required_header>
  <id_info>
    <org_study_id>LURN Phenotyping Study V8.0</org_study_id>
    <secondary_id>U01DK100017</secondary_id>
    <secondary_id>U01DK100011</secondary_id>
    <secondary_id>U01DK099932</secondary_id>
    <secondary_id>U01DK099879</secondary_id>
    <secondary_id>U01DK097780</secondary_id>
    <secondary_id>U01DK097779</secondary_id>
    <secondary_id>U01DK097776</secondary_id>
    <secondary_id>U01DK097772</secondary_id>
    <nct_id>NCT02485808</nct_id>
  </id_info>
  <brief_title>Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study</brief_title>
  <official_title>Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Phenotyping Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Research Collaborative for Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbor Research Collaborative for Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to advance our understanding of people who experience urinary
      and bladder problems. We are interested in learning about people's experiences with urinary
      symptoms and how these symptoms will be managed. We want to understand the important
      differences among people and what factors affect urinary and bladder problems. After all of
      the information is collected, we will have a better understanding of how to improve the care
      and treatment for people who have urinary and bladder problems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) was established by
      the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance our
      understanding of lower urinary tract dysfunction (LUTD) in women and men. LUTD is a term
      intended to be comprehensive and to challenge current paradigms about how symptomatic pelvic
      disorders are defined as 'diseases.' Lower urinary tract symptoms (LUTS) are likely caused
      and exacerbated by a variety of factors and thus do not represent the manifestation of a
      single disease. Clinical management of LUTD, including treatment outcomes, remains suboptimal
      since the biological and psychosocial factors that initiate, exacerbate, and modify this
      group of symptoms remain largely unknown. As an initial effort to better characterize the
      biological and psychosocial factors that initiate, exacerbate, and modify LUTS, the LURN
      investigators will establish a prospective Observational Cohort Study of men and women with
      LUTS presenting for the first time to LURN physicians.

      Information to be obtained from study participants initially (at time of enrollment) includes
      a standardized clinical examination, medical history, select testing of the lower urinary
      tract, and participants' self-report of LUTS, pelvic floor symptoms including sexual function
      and bowel symptoms, depression, anxiety, sleep patterns, stress, metabolic risk factors, and
      health-related quality of life. We will also collect serum, urine, saliva, and perineal swabs
      from men and vaginal swabs from women for storage at the NIDDK Sample Repository for future
      study by the LURN investigators and the broader research community. This information will be
      used to construct subgroups of patients who have similar symptoms, clinical presentations,
      comorbidities, pelvic floor dysfunctions, and psychological profiles. These patient
      characteristics and behaviors likely affect the evaluation, diagnosis, and/or treatment of
      LUTS. Additional information will be collected 3 months and 12 months after enrollment or 3
      and 12 months after surgery for patients receiving surgical treatment, and will include an
      interval clinical history, participants' self-report of LUTS, pelvic floor symptoms including
      sexual function and bowel symptoms, depression, anxiety, and health-related quality of life.
      We will also collect biological samples at 3 and 12 months after enrollment.

      The LURN Neuroimaging and Sensory Testing component of the study will investigate abnormal
      sensation of the lower urinary tract at the level of the organism. Subjects and controls will
      have a one-time visit soon after their baseline visit, where they will undergo an fMRI scan
      of their brain and multimodal quantitative sensory testing assessing perceptual responses to
      physical stimuli (pain and sound).

      The information to be collected from the prospective Observational Cohort Study will be
      limited and not sufficient to fully understand the pathophysiology and biology of LUTS.
      Therefore, the Observational Cohort Study will serve as the basis for further LURN studies.
      The long-term goal of the LURN is to better characterize patients with LUTD in order to
      advance future research on the pathophysiology of these
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically relevant subgroups of patients with lower urinary tract symptoms</measure>
    <time_frame>Baseline</time_frame>
    <description>Identification of patient clusters based on their symptoms, clinical assessments, and/or other characteristics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lower urinary tract symptoms</measure>
    <time_frame>baseline, 3 months, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1452</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Surgical</arm_group_label>
    <description>Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.
There will be no interventions, as this is an observational cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical</arm_group_label>
    <description>Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.
There will be no interventions, as this is an observational cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Men and women who are not experiencing lower urinary tract symptoms.
This group will undergo MRI, pain and auditory sensitivity testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuroimaging &amp; Sensory Testing</arm_group_label>
    <description>Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.
This group will undergo MRI, pain and auditory sensitivity testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None-observational</intervention_name>
    <description>For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.</description>
    <arm_group_label>Surgical</arm_group_label>
    <arm_group_label>Medical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>One time MRI scanning session examining brain structure and function in a resting state and after water consumption.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuroimaging &amp; Sensory Testing</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multimodal Automated Sensory Testing System</intervention_name>
    <description>Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuroimaging &amp; Sensory Testing</arm_group_label>
    <other_name>Pain Sensitivity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auditory Sensitivity Test</intervention_name>
    <description>Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuroimaging &amp; Sensory Testing</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood - DNA Plasma Urine Vaginal Cultures (women) Perineal Cultures (men) Saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        New patients with LUTS presenting to LURN clinical sites will be screened for participation
        based on the inclusion and exclusion criteria (below).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women presenting for new patient visits for evaluation or treatment of LUTS to
             one of the LURN physicians.

          2. Age â‰¥ 18 years.

          3. The presence of any of the symptoms reported in Table 1, based on responses to the
             LUTS Tool with a one month recall period.

          4. The ability to give informed consent and complete self-reported questionnaires
             electronically.

        Table 1: LUTS Appropriate for Study Inclusion

          -  Daytime frequency

          -  Nocturia

          -  Urgency

          -  Incontinence/leakage (various types)

          -  Poor or absent sensation of bladder filling

          -  Slow/weak stream

          -  Splitting or spraying

          -  Intermittent stream/Double voiding

          -  Hesitancy

          -  Straining

          -  Dribbling at the end of flow

          -  Paruesis (shy bladder syndrome)

          -  Poor or absent sensation of urethra during void

          -  Feeling of incomplete emptying

          -  Post-micturition dribble (delayed)

          -  Abnormal bladder or urethral sensations

        Exclusion Criteria:

          1. Gross hematuria.

          2. Significant neurologic disease or injury, including but not limited to: cerebral
             vascular accident with residual defect, Alzheimer's dementia, Parkinson's disease,
             traumatic brain injury, spinal cord injury, complicated spinal surgery, multiple
             sclerosis.

          3. Primary complaint is pelvic pain.

          4. Diagnosis of interstitial cystitis, chronic prostatitis, or chronic orchialgia.

          5. Pelvic or endoscopic GU surgery within the preceding 6 months (not including
             diagnostic cystoscopy).

          6. Current sexually transmitted infection. (deferral; subject can enroll after negative
             culture)

          7. Ongoing symptomatic urethral stricture.

          8. History of lower urinary tract or pelvic malignancy.

          9. Current chemotherapy or other cancer therapy.

         10. Pelvic device or implant complication (e.g., sling or mesh complications).

         11. Current functioning neurostimulator.

         12. Botox injection to the bladder or pelvic structures within the preceding 12 months.

         13. In men, prostate biopsy in the previous 3 months.

         14. In women, pregnancy.

         15. History of cystitis caused by tuberculosis, radiation therapy, or
             Cytoxan/cyclophosphamide therapy.

         16. Augmentation cystoplasty or cystectomy.

         17. Presence of urinary tract fistula.

         18. Current major psychiatric disorder or other psychiatric or medical issues that would
             interfere with study participation (e.g., dementia, psychosis, etc.).

         19. Inability to relay valid information, actively participate in the study, or provide
             informed consent (includes uncontrolled psychiatric disease).

         20. Difficulty reading or communicating in English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin P Weinfurt, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M Merion, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arbor Research Collaborative for Health - DCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peg Hill-Callahan, BS, LSW</last_name>
    <phone>734-369-9674</phone>
    <email>peg.hill-callahan@arborresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothy Buck, BS</last_name>
    <phone>734-369-9864</phone>
    <email>LURN-Monitors@arborresearch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Siurek</last_name>
      <phone>312-695-7748</phone>
      <email>alexis.siurek@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Brian T Helfand, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Cella, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nels Engblom</last_name>
      <phone>319-356-2910</phone>
      <email>nels-engblom@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Karl J Kreder, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine S Bradley, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Drnek, CCRP</last_name>
      <phone>734-936-5754</phone>
      <email>lagius@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Quentin Clemens, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Mueller, RN, BSN</last_name>
      <phone>314-747-8950</phone>
      <email>muellers@wudosis.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerald Andriole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Gilliam</last_name>
      <phone>919-401-1017</phone>
      <email>robin.gilliam@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Cindy L Amundsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin P Weinfurt, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Vicars, RN</last_name>
      <phone>206-598-3293</phone>
      <email>bvicars@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alice Liu, MPH</last_name>
      <email>abliu@medicine.washington.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Claire Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://nih-lurn.org</url>
    <description>Study website</description>
  </link>
  <reference>
    <citation>Coyne KS, Matza LS, Kopp ZS, Thompson C, Henry D, Irwin DE, Artibani W, Herschorn S, Milsom I. Examining lower urinary tract symptom constellations using cluster analysis. BJU Int. 2008 May;101(10):1267-73. doi: 10.1111/j.1464-410X.2008.07598.x. Epub 2008 Mar 11.</citation>
    <PMID>18336611</PMID>
  </reference>
  <reference>
    <citation>Coyne KS, Barsdorf AI, Thompson C, Ireland A, Milsom I, Chapple C, Kopp ZS, Bavendam T. Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS). Neurourol Urodyn. 2012 Apr;31(4):448-54. doi: 10.1002/nau.21202. Epub 2012 Mar 6.</citation>
    <PMID>22396308</PMID>
  </reference>
  <reference>
    <citation>Bower WF, Yip SK, Yeung CK. Dysfunctional elimination symptoms in childhood and adulthood. J Urol. 2005 Oct;174(4 Pt 2):1623-7; discussion 1627-8. Erratum in: J Urol. 2005 Dec;174(6):2428.</citation>
    <PMID>16148668</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>Bladder Symptoms</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urinary Urgency</keyword>
  <keyword>Lower Urinary Tract Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

